Healthy Adult Participants, Healthy Aging, Systemic Inflammation (hsCRP), Vitality
Conditions
Keywords
Apple extract, Fisetin, Flavonoids, polyphenols
Brief summary
The goal of this clinical trial is to learn if AppleX™ Apple Extract can help lower systemic inflammation in adults aged 45-70 with signs of low-grade inflammation. It will also look at the extract's effects on fatigue, joint comfort, and biological aging metrics. The main questions it aims to answer are: * Does taking AppleX™ Apple Extract daily lower high-sensitivity C-reactive protein (hsCRP) levels, a key marker of inflammation in the blood? * Does AppleX™ Apple Extract improve participant-reported fatigue and joint comfort? * Does the extract slow down biological or epigenetic aging metrics compared to a placebo? Researchers will compare AppleX™ Apple Extract to a placebo (a look-alike capsule that contains no active ingredients) to see if the apple extract has a measurable anti-inflammatory and healthy aging effect.
Detailed description
AppleX™ is a whole-apple extract standardized to 15% fisetin, delivering 15 mg of active fisetin within a natural polyphenol matrix of quercetin, chlorogenic acid, and procyanidins. This trial evaluates the physiological effects of continuous, lower-dose daily intake (100 mg/day) over a 24-week period, specifically targeting an aging population sample with mild systemic inflammatory burden. The study utilizes a fully decentralized clinical trial framework. Biological metrics are collected remotely utilizing home-based, finger-prick dried blood spot (DBS) micro-sampling methodologies to minimize participant burden. In addition to evaluating systemic inflammation through longitudinal tracking of high-sensitivity C-Reactive Protein (hsCRP), the protocol investigates cellular aging by assessing DNA methylation data. This exploratory analysis utilizes the TruAge testing platform (TruDiagnostic) to evaluate advanced biological clocks, including the DunedinPACE pace-of-aging algorithm and targeted organ-system sub-clocks focused specifically on immune and inflammatory aging profiles.
Interventions
DIETARY_SUPPLEMENTApple Extract
A whole-apple extract standardized to 15% fisetin within a natural polyphenol matrix of quercetin, chlorogenic acid, and procyanidins. Administered as a 100 mg capsule taken orally once daily with breakfast for 24 weeks.
OTHERPlacebo
An identical, matching inactive look-alike capsule containing microcrystalline cellulose. Administered orally once daily with breakfast for 24 weeks.
Sponsors
Nutraland USA, Inc.
Alethios, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
45 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 45-70 years at time of enrollment * Meets questionnaire-based inflammatory enrichment criteria (at least 2 of 5 risk factors, per Section 4.2) * Non-smoker (no tobacco or nicotine use within 6 months of enrollment) * Willing and able to maintain stable diet, exercise habits, and supplement use throughout the 24-week study period * No major medication changes planned during the study period * Willing to perform home-based DBS collections at T0, T12, and T24 * Access to a smartphone or computer to complete eConsent and online questionnaires * Able to provide informed consent via the Alethios eConsent platform
Exclusion criteria
* Current use of prescription anti-inflammatory medications including NSAIDs (regular use ≥3x/week), corticosteroids, or DMARDs * Diagnosis of an autoimmune or inflammatory disease (e.g., rheumatoid arthritis, lupus, IBD, multiple sclerosis) * Active or unstable cardiovascular disease requiring medication changes during the study period * History of cancer within the past 5 years (except non-melanoma skin cancer) * Regular use of supplemental fisetin, quercetin, or resveratrol within 30 days of enrollment * Pregnancy, breastfeeding, or planning to become pregnant during the study * Known allergy to apple or apple-derived products * Body mass index (BMI) \>40 kg/m²
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 24 | Baseline (Week 0) and Week 24 | Evaluation of systemic inflammation via high-sensitivity C-reactive protein levels quantified from dried blood spot micro-sampling. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Self-Reported Vitality and Energy Levels at Week 24 | Baseline, Week 12, Week 24 | Assessment of participant-reported vitality and energy using the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire. Higher scores indicate greater vitality. |
| Change from Baseline in Self-Reported Fatigue at Week 24 | Baseline, Week 12, Week 24 | Assessment of physical and mental fatigue using the Multidimensional Fatigue Inventory (MFI-20) questionnaire. Lower scores indicate less fatigue. |
| Change from Baseline in Self-Reported Joint Comfort at Week 24 | Baseline, Week 12, Week 24 | Assessment of joint comfort scores captured via standardized visual analog questionnaires. |
Countries
United States
Contacts
CONTACTDr. Bill Clark, Ph.D.
CONTACTAlethios, Inc.
PRINCIPAL_INVESTIGATORDr. Bill Clark, PhD
Natprologix, LLC
Outcome results
None listed